Fabian Flores-Borja

Dr. Fabian Flores-Borja

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Immunity
Verified
Journal Article
Closed access
PBPaul A. Blair
Paul A. Blair
LNLina Yassin Noreña
Lina Yassin Noreña
FFFabian Flores-Borja
Fabian Flores-Borja
DRDavid J. Rawlings
David J. Rawlings
DIDavid A. Isenberg
David A. Isenberg
CMClaudia Mauri
Claudia Mauri

20 February 2013 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
FFFabian Flores-Borja
Fabian Flores-Borja
ABAnneleen Bosma
Anneleen Bosma
DNDorothy Ng
Dorothy Ng
VRVenkat Reddy
Venkat Reddy
MEMichael R. Ehrenstein
Michael R. Ehrenstein
CMClaudia Mauri
Claudia Mauri
The relevance of regulatory B cells in the maintenance of tolerance in healthy individuals or in patients with immune disorders remains understudied. In healthy individuals, CD19+CD24hiCD38hi B cells suppress CD4+CD25− T cell proliferation as well as the release of interferon-γ and tumor necrosis factor–α by these cells; this suppression is partially mediated through the production of interleukin-10 (IL-10). We further elucidate the mechanisms of suppression by CD19+CD24hiCD38hi B cells. Healthy CD19+CD24hiCD38hi B cells inhibited naïve T cell differentiation into T helper 1 (TH1) and TH17 cells and converted CD4+CD25− T cells into regulatory T cells (Tregs), in part through the production of IL-10. In contrast, CD19+CD24hiCD38hi B cells from patients with rheumatoid arthritis (RA) failed to convert CD4+CD25− T cells into functionally suppressive Tregs or to curb TH17 development; however, they maintained the capacity to inhibit TH1 cell differentiation. Moreover, RA patients with active disease have reduced numbers of CD19+CD24hiCD38hi B cells in peripheral blood compared with either patients with inactive disease or healthy individuals. These results suggest that in patients with active RA, CD19+CD24hiCD38hi B cells with regulatory function may fail to prevent the development of autoreactive responses and inflammation, leading to autoimmunity.

9 December 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
FFFabian Flores-Borja
Fabian Flores-Borja
EJElizabeth C. Jury
Elizabeth C. Jury
CMClaudia Mauri
Claudia Mauri
MEMichael R. Ehrenstein
Michael R. Ehrenstein
The ultimate goal for the treatment of autoimmunity is to restore immunological tolerance. Regulatory T cells (Treg) play a central role in immune tolerance, and Treg functional abnormalities have been identified in different autoimmune diseases, including rheumatoid arthritis (RA). We have previously shown that natural Treg from RA patients are competent at suppressing responder T cell proliferation but not cytokine production. Here, we explore the hypothesis that this Treg defect in RA is linked with abnormalities in the expression and function of CTLA-4. We demonstrate that CTLA-4 expression on Treg from RA patients was significantly reduced compared with healthy Treg and is associated with an increased rate of CTLA-4 internalization. Regulation of T cell receptor signaling by CTLA-4 was impaired in RA Treg and associated with delayed recruitment of CTLA-4 to the immunological synapse. Artificial induction of CTLA-4 expression on RA Treg restored their suppressive capacity. Furthermore, CTLA-4 blockade impaired healthy Treg suppression of T cell IFN-γ production, but not proliferation, thereby recapitulating the unique Treg defect in RA. Our results suggest that defects in CTLA-4 could contribute to abnormal Treg function in RA and may represent a target for therapy for inducing long-lasting remission.

15 April 2004 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
Elizabeth C JuryElizabeth C Jury
Elizabeth C Jury
PKPanagiotis S. Kabouridis
Panagiotis S. Kabouridis
FFFabian Flores-Borja
Fabian Flores-Borja
RMRizgar A. Mageed
Rizgar A. Mageed
DIDavid A. Isenberg
David A. Isenberg
Systemic lupus erythematosus (SLE) is characterized by abnormalities in T lymphocyte receptor–mediated signal transduction pathways. Our previous studies have established that lymphocyte-specific protein tyrosine kinase (LCK) is reduced in T lymphocytes from patients with SLE and that this reduction is associated with disease activity and parallels an increase in LCK ubiquitination independent of T cell activation. This study investigated the expression of molecules that regulate LCK homeostasis, such as CD45, C-terminal Src kinase (CSK), and c-Cbl, in lipid raft domains from SLE T cells and investigated the localization of these proteins during T cell receptor (TCR) triggering. Our results indicate that the expression of raft-associated ganglioside, GM1, is increased in T cells from SLE patients and LCK may be differentially regulated due to an alteration in the association of CD45 with lipid raft domains. CD45 tyrosine phosphatase, which regulates LCK activity, was differentially expressed and its localization into lipid rafts was increased in T cells from patients with SLE. Furthermore, T cells allowed to “rest” in vitro showed a reversal of the changes in LCK, CD45, and GM1 expression. The results also revealed that alterations in the level of GM1 expression and lipid raft occupancy cannot be induced by serum factors from patients with SLE but indicated that cell-cell contact, activating aberrant proximal signaling pathways, may be important in influencing abnormalities in T cell signaling and, therefore, function in patients with SLE.

1 July 2018 in Cell Reports
Verified
Journal Article
Open access
JMJames Monypenny
James Monypenny
HMHanna Milewicz
Hanna Milewicz
FFFabian Flores-Borja
Fabian Flores-Borja
GWGregory Weitsman
Gregory Weitsman
ACAnthony Cheung
Anthony Cheung
TNTony Ng
Tony Ng
The immunosuppressive transmembrane protein PD-L1 was shown to traffic via the multivesicular body (MVB) and to be released on exosomes. A high-content siRNA screen identified the endosomal sorting complexes required for transport (ESCRT)-associated protein ALIX as a regulator of both EGFR activity and PD-L1 surface presentation in basal-like breast cancer (BLBC) cells. ALIX depletion results in prolonged and enhanced stimulation-induced EGFR activity as well as defective PD-L1 trafficking through the MVB, reduced exosomal secretion, and its redistribution to the cell surface. Increased surface PD-L1 expression confers an EGFR-dependent immunosuppressive phenotype on ALIX-depleted cells. An inverse association between ALIX and PD-L1 expression was observed in human breast cancer tissues, while an immunocompetent mouse model of breast cancer revealed that ALIX-deficient tumors are larger and show an increased immunosuppressive environment. Our data suggest that ALIX modulates immunosuppression through regulation of PD-L1 and EGFR and may, therefore, present a diagnostic and therapeutic target for BLBC.

1 January 2017 in Theranostics
Verified
Journal Article
Open access
MEMichel Eisenblaetter
Michel Eisenblaetter
FFFabian Flores-Borja
Fabian Flores-Borja
JLJae Jin Lee
Jae Jin Lee
CWChristina Wefers
Christina Wefers
HSHannah Smith
Hannah Smith
TNTony Ng
Tony Ng
Background Systemic cancer spread is preceded by the establishment of a permissive microenvironment in the target tissue of metastasis - the premetastatic niche. As crucial players in establishment of the pre-metastatic niche, myeloid derived suppressor cells (MDSC) release S100A8/A9, an exosomal protein that contributes to metastasis, angiogenesis, and immune suppression. We report the application of antibody-based single-photon emission computed tomography (SPECT) for detection of S100A8/A9 in vivo as an imaging marker for pre-metastatic tissue priming.